National Beverage Corp. vs Teradyne, Inc. — how do they compare? National Beverage Corp. trades at $30.19 (market cap $2.89B), while Teradyne, Inc. trades at $404.44 (market cap $62.34B). The key difference: Teradyne, Inc. is far larger — about 21.6× National Beverage Corp.'s market cap, and Teradyne, Inc. pays a 0.13% dividend while National Beverage Corp. pays none. Which is the better fit depends on your goals — on Pluang, investors hold National Beverage Corp. for 33 Days and Teradyne, Inc. for 37 Days on average.
| FIZZ | TER | |
|---|---|---|
Market Cap | $2.89B | $62.34B |
Volume | 553,950 | 3,368,404 |
Sector | Consumer Staples | Technology |
52-Week High | $37.73 | $483.84 |
52-Week Low | $29.20 | $132.05 |
Typical Hold Time | 33 Days | 37 Days |
Enterprise Value | $2.84B | $62.08B |
Dividend Yield | — | 0.13% |
Signals from Pluang's Aura AI — not financial advice
FIZZ trades at $30.58, up 3.31% today, but faces bearish technical signals with recent earnings misses. Revenue has stagnated around $1.2B annually, though net income margins improved to 15.55% in 2025. The company maintains strong profitability with 40.13% ROE but faces margin pressure from input costs. A $3.25 special dividend payment in July 2026 reduced shareholder equity significantly.
Outlook remains challenging with analyst consensus leaning bearish (50% sell ratings). While valuation appears reasonable (P/E 16.58), stagnant growth and consecutive earnings misses pose headwinds. The key opportunity lies in potential revenue recovery, but investors face risks from competitive pressures and ongoing margin compression.
Teradyne (TER) trades at $411.78, down 4.31% today but maintains strong technical momentum with bullish moving averages and support at $407. The company demonstrates robust fundamentals with three consecutive earnings beats, 25.77% net margins, and 36.66% ROE. Recent product launches including Magnum E2 and Iris 100 position TER to capitalize on AI-driven semiconductor testing demand. Revenue is projected to grow from $3.19B in 2025 to $4.5B in 2026 according to company guidance.
TER presents a compelling growth opportunity with dominant positioning in semiconductor testing equipment and strong AI tailwinds. However, elevated valuation multiples (P/E 54.77, P/S 14.11) require continued execution. Key risks include semiconductor cycle volatility and competitive pressure from KLAC and COHU. Analyst consensus remains bullish with $461.50 price target representing 12% upside from current levels.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
National Beverage Corp is one of the top 10 non-alcoholic beverage companies in the U.S. Its portfolio skews toward functional drinks (that is those purporting to offer health benefits) and is anchored by the popular LaCroix sparkling water trademark. Other offerings include Rip It energy drinks, Everfresh juices, and soda brands like Shasta and Faygo. The firm controls most of its production and distribution apparatus, with very little outsourcing. In terms of go-to-market, it uses warehouse distribution for big-box retailers, direct-store-delivery for convenience stores and other small outlets, and food-service distributors for the food-service channel (schools, hospitals, restaurants). It is controlled by chairman and CEO Nick Caporella, who owns over 73% of the common stock.
Read more on FIZZ →Teradyne provides testing equipment, including automated test equipment for semiconductors, system testing for hard disk drives, circuit boards, and electronics systems and wireless testing for devices. The firm entered the industrial automation market in 2015, into which it sells collaborative and autonomous robots for factory applications. Teradyne serves numerous end markets and geographies directly and indirectly with its products, but its most significant exposure is to semiconductor testing, which made up 71% of 2021 sales. Teradyne serves vertically integrated, fabless, and foundry chipmakers with its equipment.
Read more on TER →